0001213900-26-023648
SEC filingA SPAC III Acquisition Corp. reported net income of $1.3 million for fiscal year 2025, a significant improvement from a net loss of $226,383 in 2024. This positive result was driven by $2.2 million in interest income, primarily from investments held in a trust account, which offset an operating loss of $827,000 from general and administrative expenses. The company remains a blank check company with no operating revenues, having completed its initial public offering in November 2024. As of December 31, 2025, the company had total assets of $3.9 million, including $3.0 million in investments held in trust, and shareholders' equity of $420,000. The company has entered into a merger agreement with Bioserica International Limited and has until November 12, 2026, to consummate an initial business combination.
For the fiscal year ended December 31, 2025, A SPAC III Acquisition Corp. reported net income of $1,343,931, a significant improvement from the net loss of $226,383 reported for the prior year. This positive result was entirely driven by non-operating income, specifically $2,171,231 in interest earned on cash and investments held in the company's trust account. The company generated no operating revenues during the period, consistent with its status as a blank check company formed to effect a business combination. Operating activities resulted in a loss of $827,300, primarily from $214,000 in general and administrative expenses and $614,000 in legal and professional expenses. The company's financial performance reflects the typical pre-business combination phase of a SPAC, where income is derived from interest on IPO proceeds held in trust.
The company generated no operating revenues during the fiscal year, as disclosed in both the XBRL data and document text. As a blank check company incorporated for the purpose of effecting a business combination, A SPAC III has not commenced any operations that would generate revenue. The company's only income source was $2,171,231 in interest income from its bank account and investments held in the trust account. The document explicitly states: "We have neither engaged in any operations nor generated any operating revenues to date" and "We do not expect to generate any operating revenues until after the completion of our initial business combination." This is consistent with the company's business model as a SPAC in the pre-combination phase.
With no operating revenues, traditional margin analysis (gross margin, operating margin) is not applicable. The company's profitability for the period was entirely dependent on interest income exceeding operating expenses. The $2.2 million in interest income provided a substantial buffer against the $827,300 operating loss, resulting in the $1.3 million net income. The cost structure consists primarily of general and administrative expenses ($214,000) and legal and professional expenses ($614,000), which are necessary to maintain the company as a public entity and pursue business combination opportunities. The company expects to continue incurring significant costs related to being a public company and pursuing acquisition targets until a business combination is completed.
The company's cash flow statement shows net cash used in operating activities of $451,000, primarily from the net income of $1.3 million adjusted for interest earned on trust investments and changes in working capital. Investing activities provided $59.5 million in cash from withdrawals from the trust account to pay shareholder redemptions, partially offset by $60.0 million in purchases of trust investments. Financing activities used $59.8 million, mainly from $59.5 million in payments for public shareholder redemptions. The balance sheet as of December 31, 2025, shows total assets of $3.9 million, including $956,000 in current assets ($871,000 cash) and $3.0 million in investments held in the trust account. Total liabilities were $536,000, resulting in shareholders' equity of $420,000. The company reported working capital of $419,761 as of year-end.
The company has entered into a merger agreement with Bioserica International Limited on May 23, 2025, for a business combination valued at $217,860,000. The consummation of this transaction is subject to certain conditions as described in the merger agreement. Management has determined there is substantial doubt about the company's ability to continue as a going concern if it cannot complete a business combination within the combination period, which was extended to November 12, 2026. The company intends to focus on businesses in the Environmental, Sustainability and Governance (ESG) and material technology sectors. Key risk factors include the inability to complete a business combination within the required timeframe, competition for suitable targets, and potential regulatory challenges related to acquiring companies with operations in China, given that Bioserica's operations are primarily conducted through subsidiaries in China.